These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 23034559)

  • 1. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation.
    Hiemann NE; Meyer R; Wellnhofer E; Schoenemann C; Heidecke H; Lachmann N; Hetzer R; Dragun D
    Transplantation; 2012 Nov; 94(9):919-24. PubMed ID: 23034559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of non-HLA antibodies directed against endothelin-1 type A receptors (ETAR) on early renal transplant outcomes.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Krajewska M; Mazanowska O; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Nowakowska B; Hałoń A; Dawiskiba T; Chudoba P; Klinger M
    Transpl Immunol; 2014 Jan; 30(1):24-9. PubMed ID: 24184747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
    Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Antibodies Directed Against Two GPCRs, Anti-AT1R and Anti-ETAR, on Kidney Transplant Outcome.
    El Band JEK; Llorente S; Martinez-Garcia P; Alfaro R; Jimenez-Coll V; Boix F; Galián JA; Martinez-Banaclocha H; Botella C; Moya-Quiles MR; Minguela A; Legaz I; Muro M
    Curr Protein Pept Sci; 2021; 22(10):745-757. PubMed ID: 34967284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of antibodies in eluates of immunoadsorption causing humoural rejection in patients after solid organ transplantation.
    Barz D; Rummler S
    Atheroscler Suppl; 2013 Jan; 14(1):191-7. PubMed ID: 23357164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies.
    Amico P; Hönger G; Bielmann D; Lutz D; Garzoni D; Steiger J; Mihatsch MJ; Dragun D; Schaub S
    Transplantation; 2008 Jun; 85(11):1557-63. PubMed ID: 18551059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.
    Ho EK; Vlad G; Vasilescu ER; de la Torre L; Colovai AI; Burke E; Deng M; Schwartz J; Marboe C; Mancini D; Opelz G; Suciu-Foca N
    Hum Immunol; 2011 Jan; 72(1):5-10. PubMed ID: 20971146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Zmonarski S; Mazanowska O; Krajewska M; Bartoszek D; Zabińska M; Myszka M; Kamińska M; Hałoń A; Dawiskiba T; Szyber P; Sas A; Klinger M
    Transplant Proc; 2014 Oct; 46(8):2618-21. PubMed ID: 25380879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus infection does not accelerate microvasculopathy development in heart transplant recipients.
    Zakliczynski M; Krynicka-Mazurek A; Konecka-Mrowka D; Nozynski J; Zegleń S; Przybylski R; Zembala M
    Transplant Proc; 2009 Oct; 41(8):3219-21. PubMed ID: 19857714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical implication of microvasculopathy in patients post heart transplantation].
    Li L; Wang HY; Song LF; Wang LL; Guo Y; Zhao RX; Si WX; Wang QZ; Zhang J; Huang J; Zhao H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Feb; 39(2):156-9. PubMed ID: 21426752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-HLA-antibodies targeting Angiotensin type 1 receptor and antibody mediated rejection.
    Dragun D; Catar R; Kusch A; Heidecke H; Philippe A
    Hum Immunol; 2012 Dec; 73(12):1282-6. PubMed ID: 22819838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients.
    George JF; Kirklin JK; Shroyer TW; Naftel DC; Bourge RC; McGiffin DC; White-Williams C; Noreuil T
    J Heart Lung Transplant; 1995; 14(5):856-64. PubMed ID: 8800720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome.
    Reinsmoen NL; Lai CH; Mirocha J; Cao K; Ong G; Naim M; Wang Q; Haas M; Rafiei M; Czer L; Patel J; Kobashigawa J
    Transplantation; 2014 Mar; 97(5):595-601. PubMed ID: 24162250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between bridging with ventricular assist device on rejection after heart transplantation.
    Pamboukian SV; Costanzo MR; Dunlap S; Rayburn B; Westfall AO; You ZY; Hung E; McLeod M; Heroux A
    J Heart Lung Transplant; 2005 Mar; 24(3):310-5. PubMed ID: 15737758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
    Dragun D; Müller DN; Bräsen JH; Fritsche L; Nieminen-Kelhä M; Dechend R; Kintscher U; Rudolph B; Hoebeke J; Eckert D; Mazak I; Plehm R; Schönemann C; Unger T; Budde K; Neumayer HH; Luft FC; Wallukat G
    N Engl J Med; 2005 Feb; 352(6):558-69. PubMed ID: 15703421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive value of immunologic monitoring to histologic grading of heart allograft biopsy specimens: implications for therapy.
    Fisher PE; Suciu-Foca N; Ho E; Michler RE; Rose EA; Mancini D
    J Heart Lung Transplant; 1995; 14(6 Pt 1):1156-61. PubMed ID: 8719463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients.
    Pavlova YA; Malek I; Honsova E; Netuka I; Sochman J; Lodererova A; Kolesar L; Striz I; Skibova J; Slavcev A
    Tissue Antigens; 2010 Nov; 76(5):380-6. PubMed ID: 20604893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship of nodular endocardial infiltrates (Quilty lesions) to survival, patient age, anti-HLA antibodies, and coronary artery disease following heart transplantation.
    Chu KE; Ho EK; de la Torre L; Vasilescu ER; Marboe CC
    Cardiovasc Pathol; 2005; 14(4):219-24. PubMed ID: 16009321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late onset antibody-mediated rejection and endothelial localization of vascular endothelial growth factor are associated with development of cardiac allograft vasculopathy.
    Bayliss J; Bailey M; Leet A; Stein AN; Thomson NM; McLean CA
    Transplantation; 2008 Oct; 86(7):991-7. PubMed ID: 18852667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.